![]() |
CiteULike | ![]() |
epigenetics's CiteULike | ![]() |
![]() |
|
![]() |
Register | ![]() |
Log in | ![]() |
Potent antimalarial activity of histone deacetylase inhibitor analogues. |
Reviews
[Write a review of this article]
Find related articles from these CiteULike users
Find related articles with these CiteULike tags
Posting History
AbstractThe malaria parasite Plasmodium falciparum has at least five putative histone deacetylase enzymes (PfHDACs) which have been proposed as new antimalarial drug targets and may play roles in regulating gene transcription like the better known and more intensively studied human histone deacetylases (hHDACs). Fourteen new compounds derived from L-cysteine, or 2-aminosuberic acid, were designed to inhibit PfHDAC-1 based on homology modeling with human class I and II HDAC enzymes. The compounds displayed highly potent anti-proliferative activity against drug resistant (Dd2) or drug sensitive (3D7) strains of P. falciparum in vitro (IC50 3-334 nM). Unlike known hHDAC inhibitors, some of these new compounds were significantly more toxic to P. falciparum parasites than to mammalian cells. The compounds inhibited P. falciparum growth in erythrocytes at both the early and late stages of the parasite's life cycle and caused altered histone acetylation patterns (hyperacetylation) which is a marker of HDAC inhibition in mammalian cells. These results support PfHDAC enzymes as promising targets for new antimalarial drugs.
BibTeX record
RIS record